ArticleGels (Basel, Switzerland)2026
Formation and Release Enhancement of a Novel Small-Molecule Hydrogel Containing Sulindac and Meglumine.
Article in Gels (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Up to now, most hydrogel-related studies have been devoted to the preparation of drug-containing macromolecular gels via the introduction of polymer matrices, together with the clarification of their assembly mechanisms and biomedical applications. In contrast, studies concerning the design of small-molecule gel systems remain relatively limited. As gel research progresses, drug small-molecule hydrogels have attracted growing interest for formulation development. This study investigated whether designing a small-molecule hydrogel could serve as an effective solubilization approach for sulindac (SUL)-a nonsteroidal anti-inflammatory drug clinically restricted by its poor aqueous solubility. Then, a SUL small-molecule hydrogel was prepared by straightforward mixing of SUL with biologically safe meglumine (MEG) in a minimal volume of deionized water, which exhibited a characteristic three-dimensional network structure and favorable viscoelastic properties. The characterization and simulation results indicated that the hydrogel formation was contingent upon the SUL-MEG miscibility, dissolution-aggregation equilibrium and intermolecular self-assembly. Consequently, the resulting SUL-MEG hydrogel exhibited 546 times higher solubility compared to the pure SUL. Meanwhile, the SUL-MEG hydrogel demonstrated superior release kinetics and supersaturation capacity, characterized by rapid attainment of peak concentrations and sustained supersaturated release. These enhanced performances were attributed to the high-energy state of the hydrogel itself and the molecular complexation between SUL and MEG. In conclusion, this study presents a feasible formulation strategy for overcoming the poor water solubility of insoluble drugs through the development of small-molecule hydrogel formulations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.